MacroGenics starts MGC030 trial. MacroGenics stock sits 30.71 percent below high

Published on 10/20/2026 at 19:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 32.83 million versus USD 59.14 million expected. MacroGenics stock costs EUR 3.13 on October 20, 2026 at 7:08 p.m. CEST.

MGC030 trial and financial facts

MacroGenics announced first-patient dosing for MGC030 on October 15, 2026.
Second-quarter revenue was USD 32.83 million versus USD 59.14 million expected.
MacroGenics stock traded at EUR 3.13 at Lang & Schwarz on October 20, 2026 at 7:08 p.m. CEST.
Cash reached USD 113.9 million at the end of the second quarter of 2026.

MGNX, US5560991094, Illustration mit AI erstellt.

MacroGenics started the Phase 1 study of MGC030 after dosing its first patient on October 15, 2026. The company said the antibody-drug conjugate study will evaluate safety, tolerability, pharmacokinetics, immunogenicity and preliminary antitumor activity, according to GlobeNewswire.

MacroGenics plans to enroll up to 54 participants in the dose-escalation portion of the trial. MGC030 is the company's third antibody-drug conjugate in active clinical development, giving the program a defined place within its oncology pipeline.

Revenue missed the estimate

The latest reported operating picture is more mixed. In the second quarter of 2026, revenue reached USD 32.83 million, compared with the USD 59.14 million analyst estimate cited by MarketBeat. That was a USD 26.31 million shortfall against the estimate, while reported earnings per share were USD 0.31.

MacroGenics reported a second-quarter net loss of USD 69.64 million. Cash and cash equivalents stood at USD 113.91 million on June 30, 2026, while operating cash flow was negative USD 40.75 million for the quarter.

Stock remains below its yearly high

The primary listing is on Nasdaq, where the stock was trading at USD 3.52 on October 20, 2026 at 1:13 p.m. ET. The USD 1.29 to USD 5.08 52-week range places that quote 30.71 percent below the high, based on the market figures reported on October 17, 2026.

Cash and trial execution matter

For investors, the central balance is between clinical progress and funding needs. The MGC030 study adds a new development program, while the second-quarter cash balance and negative operating cash flow keep capital use relevant to the investment case. MacroGenics also operates other antibody-based programs and has collaborations with larger pharmaceutical companies.

MacroGenics stock was trading at EUR 3.13 at Lang & Schwarz on October 20, 2026 at 7:08 p.m. CEST. The primary-market quote was USD 3.52 at 1:13 p.m. ET on the same date.

The further course of trading is shown by the continuously updated real-time quote of MacroGenics stock.